DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vorapaxar
Vorapaxar
FDA Approves ZONTIVITY™ (Vorapaxar), First-In-Class PAR-1
Zontivity (Vorapaxar)
Annexes to the Annual Report of the European Medicines Agency 2014
Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains
204886Orig1s000
Neuraxial Access Or Peripheral Nerve Procedures)
Summary of the Risk Management Plan (RMP) for Zontivity (Vorapaxar)
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease
Protocol for Non-Interventional Studies Based on Existing Data TITLE PAGE Document Number: C30445781-01
Rivaroxaban Effects Illustrate the Underestimated Importance Of
Zontivity, INN-Vorapaxar
Joint Asian Pacific Association Of
Vorapaxar: a New Antiplatelet Therapy
Express Scripts Canada® Drug Trend Report 2016
Deaconess Anticoagulant & Antiplatelet Medication Reversal
Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting
Top View
High-Resolution Crystal Structure of Human Protease-Activated Receptor 1
Study Protocol
1 Pharmacodynamic Effects of Vorapaxar As An
GI Tables for Anticoagulation Discontinuation & Colonoscopy
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
Preventative Medication List
Direct Oral Anticoagulant Use: a Practical Guide to Common Clinical Challenges
Management of Antithrombotic Agents in Patients Undergoing Flexible Bronchoscopy
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Maintenance Drug List
Recent Progress and Market Analysis of Anticoagulant Drugs
Vitamin K Antagonist Oral Anticoagulants Clinical Pathway
Platelet Concentrates from 5 Donors in ABO Blood-Group-Matched Plasma) Were Obtained from the Dutch Bloodbank (Sanquin)
Dental Considerations in Patients Taking New Antiplatelet and Anticoagulant Drugs
Vorapaxar Manufacturer: Merck Sharp & Dohme Corp Drug Class1-5
Platelet Aggregation Inhibitors (PDF)
Peripheral Arterial Disease
Outcomes of Paediatric Drug Development from a Labeling
Zontivity Drug Monograph
Targeting Coagulation Activation in Severe COVID-19 Pneumonia: Lessons from Bacterial Pneumonia and Sepsis
Guidelines for ATC Classification and DDD Assignment 2021
Guideline for Reversal of Antithrombotics in Intracranial
Evolvement of EU Regulations on Innovative Medicines’ Was Accepted for Poster Presentation at the 77Th International Pharmaceutical Federation
Factors Affecting the Formation and Treatment of Thrombosis by Natural
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Management of Dental Patients Taking Anticoagulants Or Antiplatelet Drugs
Matthew Camilleri
Safe Harbor Preventative Drug List
Reference ID: 3733250
Pharmacology Update – New on the Market and Does It Work?
Saudi Moh Protocol for Patients Suspected Of/Confirmed with COVID-19
Effective January 1, 2020 *Available As Brand Only 1 of 13 THERAPEUTIC AREA DRUG CLASS GENERIC NAME BRAND NAME ANAPHYLAXIS THERA
Zontivity, INN-Vorapaxar
Vorapaxar (ZONTIVITY) Drug Monograph